User login
Key clinical point: Two algorithms identified in a new study can be used for future clinical research of relapsing-remitting multiple sclerosis (RRMS). Major finding: Using EHRs and the coded health care claims of 5,308 patients with possible MS, 837 and 2,271 were identified as having RRMS, respectively. There were also 779 patients identified using both algorithms.
Study details: Two different algorithms “unstructured clinical notes (EHR clinical notes-based algorithm) and structured/coded data (claims-based algorithms)” were used to identify patients with RRMS.
Disclosures: The investigators reported no conflicts of interest.
Citation: Van Le H, et al. Value Health. 2019 Jan;22(1):77-84. doi: 10.1016/j.jval.2018.06.014.
Key clinical point: Two algorithms identified in a new study can be used for future clinical research of relapsing-remitting multiple sclerosis (RRMS). Major finding: Using EHRs and the coded health care claims of 5,308 patients with possible MS, 837 and 2,271 were identified as having RRMS, respectively. There were also 779 patients identified using both algorithms.
Study details: Two different algorithms “unstructured clinical notes (EHR clinical notes-based algorithm) and structured/coded data (claims-based algorithms)” were used to identify patients with RRMS.
Disclosures: The investigators reported no conflicts of interest.
Citation: Van Le H, et al. Value Health. 2019 Jan;22(1):77-84. doi: 10.1016/j.jval.2018.06.014.
Key clinical point: Two algorithms identified in a new study can be used for future clinical research of relapsing-remitting multiple sclerosis (RRMS). Major finding: Using EHRs and the coded health care claims of 5,308 patients with possible MS, 837 and 2,271 were identified as having RRMS, respectively. There were also 779 patients identified using both algorithms.
Study details: Two different algorithms “unstructured clinical notes (EHR clinical notes-based algorithm) and structured/coded data (claims-based algorithms)” were used to identify patients with RRMS.
Disclosures: The investigators reported no conflicts of interest.
Citation: Van Le H, et al. Value Health. 2019 Jan;22(1):77-84. doi: 10.1016/j.jval.2018.06.014.